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MITOCHONDRIAL DYSFUNCTION AS AN UNDERLYING CAUSE OF 
BIPOLAR DISORDER  
SAMANTHA MONSON 
ABSTRACT 
 Bipolar disorder is a psychiatric disorder with alarming rates of morbidity and 
mortality. Since the pathophysiology of the disease is not well understood, it is difficult 
to develop treatments or even explain why the current treatments are successful. An 
increasingly popular hypothesis is that mitochondrial dysfunction plays a role. This paper 
examines the relationship between mitochondrial dysfunction and bipolar disorder by 
examining the following: (i) mitochondrial complex I dysfunction and oxidative damage, 
(ii) mitochondrial complex I dysfunction, epigenetic modifications, and treatment with 
lithium, (iii) post-mortem brain studies, (iv) the mtDNA common deletion, (v) calcium, 
(vi) comorbidity with mitochondrial disorders, (vii) lactate and intracellular pH levels, 
(viii) phosphocreatine, (ix) apoptosis, and (x) inositol. These studies point to a definitive 
correlation between the bipolar disorder and mitochondrial dysfunction, but it is too soon 
to determine causation. Further research is needed. 
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INTRODUCTION 
Bipolar Disorder 
 Bipolar or manic-depressive disorder consists of two states: mania (or hypomania) 
and depression (Müller-Oerlinghausen, Berghöfer, & Bauer, 2002). Mania and 
hypomania are defined by the same symptoms (Table 1), but patients are specifically 
diagnosed with mania when these symptoms drastically affect their work and/or personal 
life. While the presence of manic episodes distinguishes bipolar disorder from unipolar 
depression, an individual with bipolar disorder is more likely to be found in a depressive 
rather than a manic state. The symptoms of the depressive phase of bipolar disorder 
(Table 2) are the same as those of unipolar depression (Strakowski, 2014).  
There is no cure for bipolar disorder, and existing treatments are not as effective 
as initially thought. The relatively large prevalence, in addition to these treatment 
difficulties, makes bipolar disorder one of the most common causes of disability (Müller-
Oerlinghausen et al., 2002). More significantly, bipolar disorder proves to be deadly as 
up to 50% of patients attempt suicide and up to 15% of patients commit suicide 
(Strakowski, 2014). At this point, the pathophysiology is not well-understood. However, 
evidence is beginning to point to mitochondrial dysfunction as the culprit (Anglin, 
Mazurek, Tarnopolsky, & Rosebush, 2012). Researchers hope that elucidating the 
etiology will create better treatment options and improve the prognosis of individuals 
with bipolar disorder. 
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Table 1. Symptoms of Bipolar Disorder: Mania and Hypomania. Table adapted 
from (Strakowski, 2014). 
 
Euphoric, expansive, or irritable mood Excessive energy 
Decreased need for sleep Racing thoughts/flight of ideas 
Rapid speech Grandiosity 
Impulsive pleasure seeking Distractibility 
Mood lability Hypersexuality 
Brief periods of depressed mood Hallucinations 
Delusions Severe thought disorder 
Aggressive impulsivity Confusion 
Hyperreligiosity Extravagance 
Catatonia  
 
Table 2. Symptoms of Bipolar Disorder: Depression. Table adapted from 
(Strakowski, 2014). 
 
Depressed mood Anhedonia 
Feelings of worthlessness or excessive 
guilt 
Change in appetite and weight 
Psychomotor agitation or retardation Change in sleep pattern 
Fatigue Impaired concentration 
Suicidal thoughts or behavior  
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Mitochondrial Function 
 Mitochondria are double membrane bound organelles (Figure 1). These 
membranes create two spaces: the intermembrane space (between both membranes) and 
the matrix (bound by the inner membrane). In addition to its location, the inner 
membrane can be distinguished from the outer membrane by the presence of cristae. 
These infoldings of the inner membrane function to increase the surface area, and the 
number of cristae vary depending on the cell type in which the mitochondria reside with 
more cristae indicating an increased ATP demand (Alberts et al., 2002). 
The outer membrane contains many porins, types of transport proteins that permit 
the passage of molecules no larger than 5,000 Daltons. This implies that even proteins 
(small in size) are able to pass through the outer membrane. However, once these 
molecules enter the intermembrane space, they are unable to pass through the inner 
membrane. The lipid bilayer of the inner membrane contains a large number of 
cardiolipin, a phospholipid that contains four phospholipids as opposed to the usual two. 
Despite this structural difference (that may be responsible for the impermeability of the 
this membrane to ions), the inner membrane has many transport proteins that allow it to 
be selectively permeable to products of mitochondrial metabolism as well as molecules 
needed by the enzymes presence within the matrix (Alberts et al., 2002) 
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Figure 1: An Electron Micrograph of Mitochondria from the Adrenal Cortex. 
Figure taken from (Scheffler, 2007). 
As mitochondrial proteins are encoded by mitochondrial (mtDNA) and nuclear 
DNA (nDNA), an alteration in either could lead to mitochondrial dysfunction (P. 
Chinnery & Schon, 2003). Mitochondria rely on nDNA for proper function of the 
OXPHOS (oxidative phosphorylation) system, and researchers have determined that there 
are 97 genes related to this process. mtDNA differs from nDNA in that it is circular, 
maternally inherited, and contains fewer genes, 37 specifically. The breakdown of 
mtDNA genes and their products are described in Table 3. mtDNA mutations are 
relatively common due to errors in mtDNA repair, oxidative surroundings, and the high 
rate of replication. Thus, mutated versions of mtDNA are interspersed with the wild-type 
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mtDNA in different proportions. This varied ratio is termed heteroplasmy, and it has 
important implications in mitochondrial diseases in that that clinical manifestation is 
directly related to the degree of heteroplasmy (P. F. Chinnery & Hudson, 2013). 
 Table 3. mtDNA Genes and Their Products. Information taken from (P. F. 
Chinnery & Hudson, 2013) 
Number of Genes Gene Products Other Details 
13 genes 
One polypeptide 
component of the 
mitochondrial respiratory 
chain 
 
24 genes Mature RNA product 
22 mitochondrial tRNA 
molecules, a 16s rRNA, 
and a 12s rRNA 
 
Objective 
 Although there are many known types of mitochondrial diseases, there are 
disorders (such as multiple sclerosis, Parkinson’s disease, schizophrenia, depression, 
autism, chronic fatigue syndrome, and bipolar disorder) that are not classified as 
mitochondrial diseases themselves but have proven to involve mitochondrial dysfunction 
(Morris & Berk, 2015). The evidence presented in this thesis specifically explores the 
association between bipolar disorder and mitochondrial dysfunction in an effort to answer 
the following question: is bipolar disorder a mitochondrial disease? 
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PUBLISHED STUDIES 
Mitochondrial Complex I Dysfunction and Oxidative Damage 
Mitochondrial complex I dysfunction has been linked to bipolar disorder (Scola, 
Kim, Young, Salvador, & Andreazza, 2014). This particular type of mitochondrial 
dysfunction results in the generation of reactive oxygen species and thus oxidative 
damage to the following: proteins, lipids, and DNA (Scola et al., 2014). Such oxidative 
changes have been seen in bipolar disorder (Che, Wang, Shao, & Young, 2010). For 
example, lipid peroxidation was increased and the activity of antioxidant enzymes was 
decreased in the plasma of patients with bipolar disorder. In addition, postmortem brain 
studies showed reduced expression of the antioxidant enzymes. Furthermore, a clinical 
study on twins, one with and one without bipolar disorder, showed that the twin with 
bipolar disorder had a higher amount of lipid peroxidation when compared to the healthy 
twin. Interestingly, this lipid peroxidation decreased to normal levels when the affected 
twin was treated with mood-stabilizers, although it is not clear why (Che et al., 2010).  
Mitochondrial Complex I Dysfunction, Epigenetic Modifications, and Treatment 
with Lithium 
Several studies showed that oxidative stress can impact DNA methylation levels 
in cancer, but only one study linked this relationship to mitochondrial dysfunction, 
specifically that of complex I (Scola et al., 2014). The findings of this study suggested 
that complex I dysfunction may lead to an increase in DNA methylation and 
hydroxymethylation. Such dysfunction in epigenetic modifications was identified in 
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neuropsychiatric disorders (Dong, Gavin, Chen, & Davis, 2012), such as bipolar disorder, 
suggesting yet another possible connection between mitochondrial complex I dysfunction 
and bipolar disorder.  
The study linking complex I dysfunction and alterations in epigenetic 
modifications, and thus bipolar disorder, was conducted using rotenone, which causes 
complex I dysfunction by preventing the transfer of electrons to ubiquinone in the 
electron transport chain (ETC) (Scola et al., 2014). Using immunocytochemistry, the 
DNA methylation and hydroxymethylation levels were measured. In bipolar disorder, 
increased levels of 5-methylcytosine (5mc) and 5-hydroxymethylcytosine (5hmc) were 
identified, so these epigenetic modifications were specifically monitored. 5mc is involved 
in cell dynamics, while the function of 5hmc is not entirely understood, although it may 
be involved with the regulation of methylation/demethylation balance. With completion 
of the experiment, the researchers reached the conclusion that, in rat primary cortical 
neurons, rotenone-induced complex I dysfunction increased DNA methylation and 
hydroxymethylation, suggesting a link between mitochondrial dysfunction and bipolar 
disorder (Scola et al., 2014).  
At the same time, the researchers in this study examined the effect of lithium, a 
drug commonly prescribed for bipolar disorder, on DNA methylation and 
hydroxymethylation levels. Interestingly, the results indicated that lithium not only 
decreased the DNA methylation and hydroxymethylation to a level that approximated 
normal, but it also prevented the effects of rotenone on complex I activity (Scola et al., 
2014). 
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Post-Mortem Brain Studies 
Brain tissue heavily relies on the function of mitochondria as it utilizes 
approximately 20% of the total oxygen in the body and has a high ATP demand. In 
addition, low levels of catalase compromise its ability to attend to free radicals, which are 
primarily produced by the mitochondrial ETC (Andreazza, Wang, Salmasi, Shao, & 
Young, 2013). The following studies use the post-mortem brains of patients with bipolar 
disorder to illustrate obvious alterations of mitochondrial function present in various 
regions of these diseased brains. 
The prefrontal cortex is a commonly examined region in studies using post-
mortem brains. In a study with participants with bipolar disorder, schizophrenia, and 
controls with no psychiatric diagnosis, results supported the hypothesis that 
mitochondrial dysfunction is indeed present in the prefrontal cortex (PFC) of patients 
with bipolar disorder: these results were not seen in the brains of the controls nor in those 
of the patients with schizophrenia (Andreazza et al., 2013). One part of the experiment 
showed that there were decreased levels of mitochondrial complex I subunit proteins 
(NDUFS7 and NDUFS8) in the post-mortem PFC samples of subjects with bipolar 
disorder. Another part of the experiment looked at myelin, as its lipid composition makes 
it susceptible to lipid peroxidation. The PFC of the participants with bipolar disorder 
showed a significant increase in lipid peroxidation marker levels (8-iso and 4-
hydroxynonenal) compared to the controls.  In addition, the researchers showed that 
mitochondrial proteins are more susceptible to nitration damage, while synaptosomal 
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proteins are more disposed to oxidative damage. Interestingly, the study showed no effect 
of treatment with psychotropic drugs on the examined markers (Andreazza et al., 2013).  
The mtDNA Common Deletion 
mtDNA is more prone to mutations due to the lack of histones and absence of the 
repair machinery seen with nuclear DNA (Sequeira et al., 2012). The most frequently 
seen mtDNA deletion is called the mtDNA common deletion. It is a 4,977 base pair 
deletion that has been frequently examined in cases of bipolar disorder (Jou, Chiu, & Liu, 
2009). However, studies yield conflicting results, and further study is needed to clarify 
the discrepancy.  
One explanation relates to the region of the brain examined. It is likely that the 
mtDNA deletion ratio varies depending on the part of the brain (Sabunciyan et al., 2007). 
In one study, researchers examined the dorsolateral prefrontal cortex, and they found that 
the patients with bipolar disorder showed an increase in the common deletion versus the 
control group (Sequeira et al., 2012). However, a similar study examined the occipital 
cortex and found no such correlation, supporting the hypothesis that there are varying 
levels of the deletion in different areas of the brain (Torrell et al., 2013).  
Another explanation relates to the age of subjects. Multiple studies showed that 
there is a correlation between age and the accumulation of the common deletion 
(Sequeira et al., 2012; Shao et al., 2008). It is worth mentioning that one study did not 
find an association with age, but they noted that their conflicting results were most likely 
due to the narrow age range of their participants (Torrell et al., 2013). 
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A third explanation was posed by researchers who hypothesized that the 
pathophysiology of bipolar disorder was due to the combination of the common deletion 
and other mtDNA deletions (Kakiuchi et al., 2005). They found that the levels of 
common deletion were small, and thus not likely to play pathophysiologic role. In 
addition, their search for other deletions was unsuccessful. Despite their rejected 
hypothesis, they suggested yet another explanation: it is possible that the common 
deletion is only abundant in specific cell types (Kakiuchi et al., 2005). Two years later, 
the revised hypothesis  resurfaced. Again, it was shown that no difference in the number 
of common deletions was found when bipolar patients were compared to controls. 
Despite these results, the authors acknowledged the possibility that the techniques used in 
their research (global amplification) could not determine cell type specific changes that 
may yield different results. To alleviate this problem, the researchers suggested using 
laser micro-dissected cells in future studies (Sabunciyan et al., 2007).  
Calcium 
 Calcium (Ca2+) is a second messenger that has multiple roles, such as regulating 
neurotransmission, receptor signaling, the generation of action potentials, neuronal 
periodicity and excitability, gene expression, synaptogenesis, and cell death (Warsh, 
Andreopoulos, & Li, 2004). Mitochondria have been shown to play several roles in 
calcium homeostasis (de Sousa, Machado-Vieira, Zarate, & Manji, 2014). These 
organelles can act as calcium high-capacity sequesters as well as releasers as cytosolic 
calcium. In addition, without sufficient ATP production by mitochondria, ATP-dependent 
Ca2+ transporters are impaired, leading to a calcium imbalance (de Sousa et al., 2014). 
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 Problems with calcium arise when the levels are elevated (de Sousa et al., 2014). 
Increases in calcium levels impair post-tetanic potentiation, which results in dysfunction 
of synaptic signaling. Furthermore, high cytosolic calcium has been shown to cause stress 
and excitotoxicity, the effects of which can be remedied by mitochondrial buffering. 
Finally, the resulting cellular injury of increased calcium influx can provoke increased 
mitochondrial membrane permeability, mediated by the opening of a protein complex 
called the mitochondrial permeability transition pore. The opening of this complex results 
in the release of certain mitochondrial proteins, specifically cytochrome C and 
procaspases, that induce apoptosis (de Sousa et al., 2014). A membrane-associated 
protein called Bcl-2 also relates to this process (Soeiro-de-Souza et al., 2012). Bcl-2 is 
found in the outer mitochondrial membrane and the endoplasmic reticulum, and it has 
been shown to stabilize mitochondrial membrane integrity, preventing the release of these 
proteins and the resulting apoptosis. Interestingly, the Bcl-2 rs956572 genotype AA was 
linked to abnormal Bcl-2 expression as well as alterations in calcium homeostasis present 
in patients with bipolar disorder. These effects were reversed when the patients were 
treated with lithium (Soeiro-de-Souza et al., 2012).  
Bipolar disorder has been associated with disruptions in calcium homeostasis 
(Warsh et al., 2004). Using lymphoblastoid cells, one group set out to determine the 
mechanism responsible for the altered intracellular calcium signaling seen in patients 
with bipolar disorder (Tadafumi Kato et al., 2003). In addition to measuring calcium 
responses to platelet-activating factor and thapsigargin, they looked at the effect of 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), which is of interest as it is a 
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mitochondrial uncoupler that impacts mitochondrial calcium uptake. Their study showed 
that the calcium response to the CCCP depended on the mtDNA 5178/10398 haplotype, 
indicating that this (bipolar disorder associated) mtDNA polymorphism, by affecting the 
mitochondrial calcium regulation, may be a risk factor for bipolar disorder (Tadafumi 
Kato et al., 2003). 
Through the examination of the mtDNA sequence in 35 hybrid cell lines, a 
different study found two polymorphisms, 8701A and 10398A that resulted in an increase 
in the basal fluorescence ratio (ratio of 480 nm excitation to 410 nm excitation) of 
mitochondria-targeted radiometric Pencam (RP), a calcium indicator (Kazuno et al., 
2006). While the two polymorphisms are closely linked, 10398A has been previously 
associated with bipolar disorder. In both mtSNPs (single nucleotide polymorphisms), an 
alanine is substituted for a threonine. In the 10398A/G mtSNP, the substitution occurs at 
the C terminus of a subunit of complex I (NADH; ubiquinone oxidoreductase) called 
ND3. In the 8701A mtSNP, the substitution occurs at the F0 subunit 6 of complex V 
(ATP synthase), which is called ATPase6. Complex I is responsible for the generation of 
a proton gradient across the inner mitochondrial membrane, and Complex V takes 
advantage of this proton gradient to produce ATP. In addition to producing ATP, this 
proton gradient is considered the driving force of mitochondrial calcium uptake (Kazuno 
et al., 2006). 
Comorbidity with Mitochondrial Diseases  
 Patients with mitochondrial disease are often characterized by various types of 
physical impairments. However, more and more research is identifying comorbid 
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psychiatric symptoms (Clay, Sillivan, & Konradi, 2011). One study examined 19 patients 
with known primary mitochondrial DNA disorders as well as 10 controls with hereditary 
sensorimotor neuropathy (HN) (Inczedy-Farkas et al., 2012). Their goal was to assess the 
presence of psychiatric symptoms in the mitochondrial disease patients. Eight 
mitochondrial disease patients had a past psychiatric diagnosis (42%), six had a current 
psychiatric diagnosis (31%), and five had both past and current psychiatric diagnoses 
(47%). In contrast, only three patients had both a past and current psychiatric diagnosis in 
the control group with a lifetime prevalence of 30%. The specific results of the Structured 
Clinical Interviews of DSM-IV axis-I (SCID-I) and axis-II (SCID-II) disorders are 
outlined in Table 4. The study concluded that there is a high association of psychiatric 
symptoms with mitochondrial disorders. 
Table 4. Gender, Age, and Results of SCID-I and SCID-II Scores of Mitochondrial 
Disease Patients. Adapted from (Inczedy-Farkas et al., 2012) 
ID Gender Age 
Past 
Diagnosis 
SCID-I 
Current 
Diagnosis 
SCID-II 
Personality 
Disorder 
SCID-II 
1 Female 34 
Mixed-
anxiety 
depressive 
disorder 
Major 
depressive 
disorder 
Avoidant 
2 Female 51 Dysthymia - - 
3 Female 34 - - - 
4 Female 16 - - - 
5 Male 32 - Dysthymia 
Personality 
disorder 
NOS 
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6 Female 61 - - - 
7 Male 34 
Adjustment 
disorder 
with 
depressed 
mood 
- - 
8 Male 34 
Adjustment 
disorder 
with 
depressed 
mood 
- Avoidant 
9 Female 59 - - Obsessive-compulsive 
10 Male 23 - - - 
11 Female 34 - - - 
12 Female 40 - - - 
13 Female 38 Bipolar II disorder 
Bipolar II, 
current 
episode 
depressive 
- 
14 Male 20 - - - 
15 Female 22 - - Obsessive-compulsive 
16 Female 39 
Major 
depression 
with 
psychotic 
features 
Major 
depressive 
disorder 
Personality 
disorder 
NOS 
17 Male 20 - - Avoidant 
18 Female 37 PTSD Bipolar II, 
current 
Personality 
disorder 
NOS 
	15 
episode 
depressive 
19 Female 41 Postpartum depression 
Bipolar I, 
latest 
episode 
depressive 
- 
 
Another article summarized the findings of 19 case reports, all of which link 
mitochondrial disease with psychiatric illnesses (Fattal, Budur, Vaughan, & Franco, 
2006). The specific diagnoses are listed in Table 5. Researchers are becoming 
increasingly aware of the comorbidity between psychiatric illnesses and mitochondrial 
diseases, but the comorbidity with bipolar disorder, specifically, remains to be evaluated. 
Table 5. Case Reports of Mitochondrial Disease Patients with Psychiatric Problems. 
Adapted from (Fattal et al., 2006) 
ID Gender Mitochondrial Disorder 
Psychiatric 
Symptoms (Age of 
Onset) 
1 Female MELAS, atypical 
Schizophrenia, 
progressive 
dementia (23 years) 
2 Male MELAS 
Psychosis: auditory 
hallucinations, 
persecutory 
delusions, 
disorganized 
behavior, 
progressive 
dementia (25 years) 
3 Male MELAS 
Psychosis: visual 
hallucinations, 
somatic delusions, 
hyperactivity, 
	16 
progressive 
dementia (32 years) 
4 Male MELAS 
Psychosis: auditory 
and visual 
hallucinations, 
delirium, IQ: 
87→43 (19 years) 
5 Female MELAS; A3243G mutation of tRNA 
Psychosis: auditory 
hallucinations, 
paranoid ideation, 
delusions of 
reference (22 years)  
6 Male 
Mitochondrial 
encephalomyopathy; 
C3256T mutation of 
tRNA 
Psychosis: 
“delusion”, 
“confusion”, 
progressive 
dementia (29 years) 
7 Male A3243G mutation of mtDNA 
Psychosis: auditory 
hallucinations, 
persecutory 
delusions, frontal 
lobe syndrome, IQ: 
71→59 (31 years)  
8 Male MELAS; A3243 mutation of tRNA 
Psychosis (21 
years) 
9 Female Kearns-Sayre syndrome 
Bipolar disorder, 
decreased 
intellectual 
functioning (23 
years) 
10 Male 
Mitochondrial 
myopathy and 
decreased MARPs 
MDD, transient 
auditory and visual 
hallucinations (22 
years) 
11 Male G3274A mutation in tRNA 
MDD with 
psychosis, suicidal 
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ideation; deficits in 
memory, attention, 
and orientation (27 
years) 
12 Female 
Autosomal 
dominant PEO, 
multiple mtDNA 
deletions 
MDD (19 years) 
13 Male A3243G mutation of tRNA MDD (22 years) 
14 Male A3243G mutation of tRNA 
MDD recurrent: IQ 
95 (47 years) 
15 Female A3243G mutation of tRNA 
Panic disorder, 
agoraphobia (37 
years) 
16 Female A3243G mutation of tRNA 
Social phobia; IQ 
98 (25 years) 
17 Male A3243G mutation of tRNA 
Simple phobia; IQ: 
103 (35 years) 
18 Male MELAS; 3243 mutation of tRNA 
Personality change: 
poor impulse 
control, inactivity, 
apathy (34 years) 
 
Lactate and Intracellular pH Levels 
 Metabolic studies of bipolar disorder patients have illustrated a trend in which 
these patients generally show an increase in lactate levels and a decrease in pH (Stork & 
Renshaw, 2005). These two levels appear to be inversely linked, and the increased levels 
of lactate has been shown to result from mitochondrial dysfunction. When the respiratory 
chain component of cellular metabolism is impaired, the cell defaults to anaerobic 
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glycolysis for energy production. When this occurs, pyruvate is converted into lactate 
when it is used as a hydrogen acceptor in order to form NAD from NADH. This 
relationship between lactate concentration and intracellular pH is reinforced by an animal 
study that illustrated this inverse relationship when mitochondrial failure was induced 
with the application of cyanide (Clausen, Zauner, Levasseur, Rice, & Bullock, 2001). 
 A study that examined cerebrospinal fluid (CSF) lactate concentrations in bipolar 
disorder patients of varying states (depressed, euthymic, or manic) showed an increase in 
the lactate levels (Regenold et al., 2009). However, it is important to distinguish between 
the states as various other studies show that the lactate and pH levels depend on the state 
of the bipolar disorder patients (Stork & Renshaw, 2005). The studies conducted on 
bipolar disorder patients in these varying states are discussed below and summarized in 
Table 6. 
 Several studies looked at patients with bipolar disorder in the euthymic state. One 
examined the intracellular pH in the basal ganglia of 13 bipolar disorder patients and 
found that the pH was significantly reduced. These researchers acknowledged that 
dysfunctional metabolism may be responsible for this alteration in pH (Hamakawa et al., 
2004). This decrease in intracellular pH in euthymic bipolar disorder patients compared 
to controls was found when researchers examined the frontal cortex as well (T. Kato, 
Takahashi, Shioiri, & Inubushi, 1993). In addition, the intracellular pH levels in the 
manic and depressed state were found to be approximately normal (and thus higher than 
that seen in the euthymic state) (Tadafumi Kato & Kato, 2000). Although the reason for 
this discrepancy in intracellular pH between states is not known, it was suggested that the 
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pH in depressed and manic states are altered in response to an over-activation of 
monoaminergic systems. This is because noradrenaline has been linked to the activation 
of the Na+/H+ exchanger, which increases intracellular pH (Tadafumi Kato & Kato, 
2000). It is important to note, however, that a more recent study contradicted these 
findings, in that no difference was seen in the intracellular pH of euthymic and manic 
patients (Weber et al., 2013). Weber et al. acknowledged this contribution and attributed 
the different results to the fact that the age, brain regions examined, and medication status 
differed between studies (2013). 
 A study with 32 medication-free bipolar disorder patients looked at the lactate 
levels while these patients were in depressed or mixed-mood states (Dager et al., 2004). 
Like the majority of the studies looking at euthymic bipolar disorder participants, they 
found elevated lactate levels when examining gray matter. Previously, lactate was 
believed to be a by-product of glycolysis only. However, more recent evidence suggests 
that lactate has an important role in brain energetics. While a small fraction of energy 
used during normal neuronal activation is from glycolysis, this amount is increased to 
one-third of total energy expenditure during rapid neuronal firing, which could explain 
the elevated gray matter lactate levels seen in bipolar disorder in the study by Dager et al. 
(2004).  
 Finally, one study examined the change in lactate levels as the participants 
switched from a manic state to a euthymic state (Brady et al., 2012). They originally had 
15 patients, but only seven returned when in a euthymic state. These researchers found 
that the bipolar disorder participants had lactate levels similar to the controls when in a 
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manic state. However, the lactate concentrations were significantly reduced when these 
patients were in the euthymic state (Brady et al., 2012). 
Table 6. Studies of Lactate Levels and/or Intracellular pH in Bipolar Disorder 
Patients of Varying States 
Author Year Participants Focus Results 
Brady et al. 2012 
7 bipolar type I 
patients in a 
manic state and 
later in a 
euthymic state 
Anterior 
cingulate 
cortex 
(ACC) 
Same lactate 
levels in mania 
and decreased 
lactate levels in 
euthymia 
Dager et al. 2004 
32 medication-
free bipolar type 
I and bipolar 
type II patients in 
a primarily 
depressed or 
mixed-mood 
state 
Gray matter Increased lactate levels 
Hamakawa et 
al. 2004 
13 patients with 
bipolar disorder 
in a euthymic 
state 
Basal 
ganglia 
Decreased 
intracellular pH 
Kato et al. 1993 
17 patients with 
bipolar disorder 
in the euthymic 
and manic states 
Frontal 
cortex 
Increased 
intracellular pH 
in the manic 
state compared 
to the euthymic 
state, where 
manic and 
depressed state 
levels are 
approximately 
normal; 
decreased 
intracellular pH 
in the euthymic 
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state compared 
to the controls 
Regenold et al. 2009 
15 patients with 
bipolar type I 
disorder in 
various states 
CSF Increased lactate levels 
Weber et al. 2013 
14 bipolar 
disorder patients 
in the euthymic 
state and 19 
bipolar disorder 
patients in the 
manic state 
Anterior 
cingulate 
cortex 
(ACC)  
Decreased 
intracellular pH 
in manic 
compared to the 
controls 
 
Phosphocreatine 
 Phosphocreatine (PCr) is molecule of interest because it is an indicator of the 
status of cellular energy, and a decreased PCr concentration suggests decreased energy 
metabolism, which may be caused by mitochondrial dysfunction (Frey et al., 2007). PCr 
is formed from the reaction of creatine (Cr) and ATP in the mitochondria, and the 
reaction is catalyzed by creatine kinase (CK) (see Figure 2 below). PCr transports high 
energy phosphates from mitochondria to the cytosol (Tadafumi Kato & Kato, 2000), and 
it is necessary for cellular homeostasis (Frey et al., 2007). On the other hand, Cr 
stabilizes mitochondrial CK, preventing a preliminary aspect of apoptosis in which the 
mitochondrial transition pore is opened.  
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Figure 2: PCr is formed from the reaction of Cr and ATP, and the reaction is 
catalyzed from CK. Figure taken from (Frey et al., 2007). 
 Decreased PCr has been seen in mitochondrial encephalopathies as well as in 
bipolar disorder (Tadafumi Kato & Kato, 2000; Young, 2007). This decrease in PCr, 
along with a decrease in ATP, suggest that mitochondrial dysfunction is the culprit 
(Tadafumi Kato & Kato, 2000). However, research also shows that decreased PCr is not 
universal throughout the brain. An in vivo phosphorous-31 magnetic resonance 
spectroscopy study using 12 non-medicated, euthymic bipolar disorder subjects and 16 
controls revealed that this decrease in PCr was asymmetrical in the frontal lobe of the 
brain. Specifically, there was a higher right-to-left ratio of PCr (Deicken, Fein, & Weiner, 
1995).  
 Epidemiological differences between bipolar disorder type I and type II are well-
known, so researchers realized that it would be beneficial to examine PCr in patients with 
these different subtypes of the disorder (Tadafumi Kato et al., 1994). A study by Kato et 
al. did just that and found reduced brain PCr levels in the patients with bipolar disorder 
type II (1994). Not only that, but this decrease was seen in the euthymic, depressive, and 
hypomanic states. The researchers concluded that the reduction in PCr was trait-
dependent (upon the type of bipolar disorder) instead of state-dependent (euthymic vs. 
depressed vs. manic) (Tadafumi Kato et al., 1994). 
 These researchers went further and hypothesized why this decrease in PCr was 
observed (Tadafumi Kato et al., 1994). They indicated that there are four possible reasons 
why there is a decrease in PCr, all of which are clear when looking at the reaction 
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illustrated in Figure 2: (1) an increase in energy demand, (2) a decrease in CK activity, 
(3) a decrease of ATP synthesis, and (4) a decreased concentration of creatine.  
Upon closer examination, a few of these hypothesized explanations were found to 
be untrue. First, an increase in energy demand cannot be applied to this situation due to 
the fact that brain glucose metabolism is reduced in the frontal lobes of patients with 
bipolar disorder. Second, a reduction in CK activity could not be feasible as this study 
showed that the reduction of PCr levels only occurred in the patients with bipolar 
disorder type II while intracellular pH and intracellular magnesium concentration, two 
regulators of CK, were shown to be altered in all patients with bipolar disorder. However, 
intracellular magnesium levels may be a possible indicator because serum magnesium 
concentration is correlated to the severity of depressive symptoms, although it must be 
confirmed as it was not assessed in this study.  
The third possible explanation, a reduction in ATP synthesis, cannot be 
eliminated for two reasons: (1) mtDNA depletion has been seen in those with depressive 
disorders, and (2) a patient with mitochondrial myopathy was reported to show manic-
depressive symptoms. In addition, those with migraines have been shown to have reduced 
brain PCr, mitochondrial dysfunction has been commonly linked to migraines, and 
bipolar type II patients have been frequently noted to have comorbid migraines 
(approximately 25%) (Tadafumi Kato et al., 1994). 
Finally, in a study that examined the CSF of bipolar disorder patients (80% of 
which had type II), researchers noted a decrease in creatine in these subjects compared to 
those with major depression. Thus, the probable causes of lower PCr in bipolar disorder 
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type II patients are as followed: (1) decreased CK activity, (2) increased intracellular 
magnesium concentration, (3) reduction of brain creatine content, and (4) genetic 
mitochondrial abnormalities (Tadafumi Kato et al., 1994). 
 A later study took this further and examined CK mRNA expression in the 
dorsolateral prefrontal cortex (DLPFC) and hippocampus (HIP) of patients with bipolar 
disorder (MacDonald, Naydenov, Chu, Matzilevich, & Konradi, 2006). They examined 
two isoforms of CK that are known to be present in these brain regions: CKB, which is 
expressed in oligodendrocytes and astroglia, and CKMt1, which is expressed in the 
mitochondria of neurons. Both of these isoforms were found to be downregulated in the 
patients with bipolar disorder (MacDonald et al., 2006). 
 Although the aforementioned studies seem to suggest that decreased PCr levels 
are relevant to bipolar disorder, problems arise when the PCr levels are examined in 
adolescent bipolar disorder patients. In one study using subjects between the ages of 11 
and 20, no difference was seen in the levels of PCr when comparing eight bipolar 
disorder patients with eight controls (Sikoglu et al., 2013). Furthermore, another study 
that examined participants of ages 13 to 18, showed an increase in PCr compared to the 
controls. Although this contradicted their hypothesis based on previous studies with adult 
patients, this was not altogether surprising as pediatric and adult bipolar disorder patients 
have been found to have different neurochemical characteristics, suggesting that the brain 
metabolism may vary with age (Shi et al., 2012).  
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Apoptosis 
 Apoptosis involves the self-destruction of cells (Tsujimoto, 1998). It is 
characterized by phenomena listed in Table 7 (Fries et al., 2014). Apoptosis is used for 
developmental sculpturing, homeostasis of tissues, and the removal of cells that are no 
longer needed or are damaged (Tsujimoto, 1998). In addition, neural apoptosis is an 
important part of neural development, but apoptotic dysfunction can causes “synaptic 
apoptosis”, which is the atrophy of synapses or neurites (de Sousa et al., 2014).  
Table 7. Phenomena that Characterize Apoptosis. Information taken from (Fries et 
al., 2014). 
Rounding of the cell 
Pyknosis (decrease in cell size) 
Condensation of chromatin 
A small amount of cytoplasmic ultrastructural organelle modifications 
Nuclear fragmentation 
Blebbing of the plasma membrane 
Phagocyte engulfment 
  
 Mitochondria play a role in both the intrinsic and extrinsic apoptotic pathways (de 
Sousa et al., 2014). In the intrinsic pathway, certain stimuli such as increased levels of 
cytoplasmic calcium or reactive oxygen species, or even the activation of Bcl-2 family 
proteins, lead to caspase activation, which causes apoptosis. In the extrinsic pathway, a 
change in membrane permeability to leaked proapoptotic factors occurs due to the 
activation of extracellular death receptors. 
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 Systemic changes seen in patients with bipolar disorder include increased 
inflammatory markers, reduced neurotrophic factors, oxidative stress, and DNA damage 
(Fries et al., 2014). All of which characterize systemic toxicity. These dysfunctional 
cellular resilience mechanisms lead to increased susceptibility to cell death when exposed 
to a stressful environment.  
Certain apoptotic factors undergo changes in bipolar disorder, including DNA 
damage in peripheral blood, apoptotic serum activity increase, differential expression of 
cell death and survival molecules in peripheral blood mononuclear cells (PBMCs), and, 
of particular interest, mitochondrial dysfunction (Fries et al., 2014). Thus, cell death 
clearly plays a role in bipolar disorder, and this connection even involves mitochondrial 
dysfunction. Fries et al. hypothesized that specific transmembrane receptors in PBMCs 
identify peripheral molecules that act as extracellular stress signals, such as tumor 
necrosis factor (TNF-a), that induce extrinsic apoptosis. TNF-a is increased in the serum 
of bipolar disorder patients and induces apoptosis by activating caspases. Other research 
shows that bipolar disorder patients’ lymphocytes have decreased expression of HSP70, 
an anti-apoptotic factor, and BAX levels in the cytoplasm. This suggests that they were 
relocated to the mitochondria, a movement that induces apoptosis (Fries et al., 2014). 
 Figure 3 details targets for drug development (de Sousa et al., 2014), one of which 
includes apoptotic mechanisms. These targets are promising, but mood stabilizers and 
atypical antipsychotics, which are used in the treatment of bipolar disorder, already 
regulate some of these abnormalities. For example, lithium has been shown to regulate 
apoptosis (de Sousa et al., 2014). When rotenone, a substance that induces complex I 
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dysfunction, was given to rats, an annexin V assay showed that the rotenone cause an 
increase in cells in early and late apoptosis, and lithium decreased the amount of 
apoptosis (Scola et al., 2014). 
 
Figure 3: Targets for drug development include complex I of the ETC, monoamine 
oxidases, mitochondrial transport, apoptotic mechanisms, and calcium regulation. 
Note: Monoamines (MA) generate reactive oxygen species (ROS) via monoamine 
oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Figure taken from (de 
Sousa et al., 2014). 
Inositol 
There are three sources of inositol: synthesis from glucose 6-phosphate via MIPS 
(1-D-myo-inositol-phosphate synthase), inositol phosphate dephosphorylation from 
inositol-containing membrane phospholipid breakdown, and myo-inositol transporters’ 
uptake of extracellular fluid (Deranieh & Greenberg, 2009).  
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The high inositol levels in the neurons of patients with bipolar disorder is likely 
due to the high demand of membrane phospholipids, which are required for plasticity and 
formation of synapses in neurons (Deranieh & Greenberg, 2009). Most research 
examining inositol depletion has focused on the phosphoinositide cycle, but inositol also 
plays a role in various intracellular signaling molecules that relate to the following: 
phospholipid synthesis, the UPR (unfolded protein response), and protein secretion. 
Researchers have proposed that the impaired phospholipid metabolism in bipolar disorder 
is due to the changes in choline, myo-inositol, inositol monophosphate, and 
phosphomonoester levels. The decrease in energy due to mitochondrial dysfunction is 
responsible for the changes listed above. In addition, inositol plays a role in the 
expression of over 712 genes, and inhibition of inositol alters the expression of hundreds 
of these genes, which are involved in important pathways (Deranieh & Greenberg, 2009). 
VPA (valproic acid), carbamazepine, and lithium, three bipolar disorder 
medications, all cause reduced levels of inositol, although by different mechanisms 
(Deranieh & Greenberg, 2009). The lack of a common mechanism leads to the following 
question: why does inositol depletion have therapeutic effects?  
Research on VPA by Ju and Greenberg showed that treatment with VPA led to 
increased levels of inositol, which then led to an elevation in cardolipin (a phospholipid 
required for efficient mitochondrial function) (2003). 
Though it is not entirely clear why, carbamazepine seems to lead to inositol 
depletion through uptake inhibition (Deranieh & Greenberg, 2009).  
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Research by Toker and Agam addressed the inositol depletion hypothesis and 
lithium. This was first described by Berridge et al., and it states that the inhibition of 
various enzymes in the PI (phosphatidylinositol cycle) causes the mood-stabilizing action 
of lithium (Toker & Agam, 2014). Specifically, it works through the inhibition 
(uncompetitive) of inositol monophosphatase (IMPase), which causes the down-
regulation of the PI cycle. Normally, neurotransmitters (which are also thought to play a 
role in disorders such as bipolar disorder) are thought to play a role in the hydrolysis of 
PIs to second messenger molecules through specific subtypes of receptors as well as G-
protein activation (van Calker & Belmaker, 2000). These second messenger molecules 
include DAG (diacylglercerol) and IP3 (inositol-1,4,5-trisphosphate). The former is 
responsible for the activation of PKC (protein kinase C) and the latter is responsible for 
the activation of intracellular Ca2+ release. In addition, IP3 is metabolized through serial 
phosphorylation and dephosphorylation to myo-inositol, which along with CDP-DAG, is 
used to resynthesize PIs. Hydrolysis of inositol monophosphate to myo-inositol is the 
final step in the IP3 metabolism, and it is inhibited by lithium ions (if given at the 
therapeutic concentration). The inositol-depletion hypothesis suggests that the resulting 
decrease in myo-inositol leads to fewer PI-dependent second messenger molecules (van 
Calker & Belmaker, 2000).  
Lithium leads to cellular signaling regulation, but the effects of lithium in the 
context of inositol have proven to relate to another process called autophagy (Toker & 
Agam, 2014). This process leads to the removal of misfolded proteins and protein 
aggregations. One study looked at lithium treatment versus knockouts of two genes 
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(separately) that play a role in the PI cycle (Toker et al., 2014). They found that the 
knockouts of the two genes mimicked the effect of lithium, and all three showed a 
favorable alteration in mitochondrial function. The mechanism behind the inositol 
depletion’s impact on mitochondrial activity is unknown at this point, but the induced 
autophagy may play a role. Mitochondrial fission creates two daughter organelles, and 
this process often leads to an unequal ratio of functional to dysfunctional organelles. The 
latter can be degraded by autophagy (called mitophagy in this case), which leads to an 
increase in the proportion of healthy mitochondria, which is consistent with the 
experiments with lithium and the gene knockouts (Toker & Agam, 2014). 
Homozygote inositol monophophatase 1 (IMPA1) knockout mice are, by 
definition, unable to synthesize inositol, mimicking animals treated with lithium. In a 
study by Shtein et al., those mice, in addition to lithium-treated wild type mice, were fed 
an inositol-deficient diet. In this experiment, pilocarpine, a cholinergic agonist, is used to 
assess the effect of this inositol-deficient diet, which in conjunction with lithium 
treatment, is known to improve the function of the lithium. In other words, the 
pilocarpine is used to see if the inositol-deficient diet improves the action of lithium. The 
study showed that both experimental groups had increased cholinergic behavior, which 
indicates enhanced action of lithium. These results raise the possibility of a practical 
application in which an inositol-deficient diet is used to enhance lithium’s action in a 
clinical setting (Shtein, Agam, Belmaker, & Bersudsky, 2015). 
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We cannot assume that lithium, VPA, and carbazemine work therapeutically 
because of inositol depletion, although it is certainly tempting as they all result in such a 
decrease.  
 
 
DISCUSSION  
 This paper examined various types of mitochondrial dysfunction that correlate 
with bipolar disorder. Some of these forms of mitochondrial dysfunction may very well 
be underlying causes of bipolar disorder. However, almost every consulted study 
concludes that more research is needed as there were many caveats. 
 While it is useful to study the post-mortem brain, its examination comes with 
problems such as the pH variability, post-mortem interval, and the small sample sizes as 
noted by Scola et al. (2014). Another study that incorporated the use of post-mortem 
brains noted that the retrospective view of the patients’ histories could lead to some 
errors. In addition, some of the participants were included even though they were known 
to have substance abuse problems and many were medicated, which could have 
potentially confounded the data (Che et al., 2010). A third study acknowledged storage 
conditions as another post-mortem brain limitation, but they controlled for post-mortem 
interval and pH (Andreazza et al., 2013). In addition, they acknowledged that they only 
looked at a specific brain region, the pre-frontal cortex, and further examination of 
alternative brain regions would be beneficial. The importance of examining different 
brain regions was an issue that was also raised in the mtDNA common deletion studies, 
in which the common deletion varies from region to region (Sequeira et al., 2012). 
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However, this study acknowledged that, although they looked at different brain regions, 
they did not look at specific differences between different parts of these regions nor did 
they examine specific differences between the cells. In the future, the paper suggested the 
use of laser capture microdissection to do the latter (Sequeira et al., 2012).  
 In the studies on lactate concentration and intracellular pH, it seems clear that 
there is an obvious trend that points to mitochondrial dysfunction as an underlying cause. 
However, the majority of studies focused on bipolar patients in the euthymic state and 
only one study looks at the different states within the same participants. In addition, 
almost every study looks at different brain regions. It would be interesting to see some of 
these studies replicated in the same brain regions but during different states.  
Many of the studies that have illustrated a decrease in PCr in bipolar disorder 
patients have been conducted using non-medicated participants. Studies that used 
medicated patients have been unable to replicate this result (Frey et al., 2007). For 
example, one study showed that when comparing medicated to non-medicated bipolar 
disorder patients, the medicated subjects actually had lower PCr levels than those that 
were non-medicated (Shi et al., 2012). Further research is needed. 
Finally, the papers on the comorbidity of bipolar disorder and mitochondrial 
disorders simply link mitochondrial disorders with psychiatric symptoms in general, not 
specifically bipolar disorder. In the study by Inczedy-Farkas et al., only three patients of 
the 19 presented were diagnosed with some form of bipolar disorder (2012). Similarly, in 
the study by Fattal et al., only one patient of the 18 listed was diagnosed with bipolar 
disorder (2006). While these studies illustrate a high prevalence of psychiatric problems 
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among individuals with mitochondrial diseases, more research must be conducted on the 
correlation with bipolar disorder exclusively.  
In summary, there are many limitations to the studies that have been conducted on 
bipolar disorder and mitochondrial dysfunction. However, that does not undermine the 
relationship between the two. Through the examination of the published research, it 
seems clear that there is some correlation, but it is too soon to claim causation. Further 
research is needed and, based on the promise of these studies, warranted. 
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